Physician profile
Daniel Shats
NPI 1710005970
$831.57
in general payments reported to CMS, 2019-2025
13 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.83 · 2023: $12.92 · 2024: $39.77 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.12 | 2022-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $153.70 | 2025 | |
| Genzyme Corporation | $70.17 | 2025 | |
| Madrigal Pharmaceuticals | $60.05 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.77 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $48.54 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $46.64 | 2022-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $44.22 | 2025 | Voquezna |
| Ardelyx, INC. | $36.65 | 2025 | Ibsrela |
| Novo Nordisk INC | $24.05 | 2025 | Wegovy |
| Stryker Corporation | $17.72 | 2025 | Neptune, Pedi-Pom |
| Ipsen Biopharmaceuticals, INC | $17.42 | 2025 | Iqirvo |
| Qol Medical, LLC | $16.52 | 2025 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.